Vertex Pharmaceuticals (VRTX) said Friday it has made a reimbursement agreement with National Health Service England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy.
The reimbursement agreement coincides with the UK National Institute for Health and Care Excellence recommending Casgevy's use by the NHS, the company said.
Administration of the therapy requires experience in stem cell transplantation, and Vertex said it is working with hospitals to establish treatment centers.
Shares of the company were up more than 8% in Friday's premarket activity.
Price: 475.00, Change: +36.60, Percent Change: +8.35
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。